Cointime

NOVACYT

company

About

NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.

  • 101 - 250

Highlights

Total Funding Amount
$5M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$5M
Industries
Biotechnology,Health Care,Health Diagnostics,Life Science,Professional Services
Founded date
Jan 1, 2006
Number Of Employee
101 - 250
Operating Status
Active

The Novacyt Group is a rapidly growing, international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie
in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and
serology markets as do its global partners, which include major corporates.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$5M
NOVACYT has raised a total of $5M in funding over 2 rounds. Their latest funding was raised on Aug 4, 2015 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 4, 2015 Post-IPO Debt $5M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
NOVACYT is funded by 2 investors. YA Global Master SPV and Kreos Capital are the most recent investors.
Investor Name Lead Investor Funding Round
YA Global Master SPV — Post-IPO Debt
Kreos Capital — Post-IPO Debt
Cointime
เนื้อหา
บริษัท